Canopy Growth Corp. Stock (TSX: WEED) (NYSE: CGC) - Investor Dashboard

Canopy Growth Corp.
Toronto Stock Exchange: WEED
New York Stock Exchange: CGC
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 3211 at 03/31/19
Established: 2012
Acting CEO Mark Zekulin


Fiscal Year-End: March
Facilities: 13
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: ~83,400 at 12/31/18
Headquarters: Smith Falls, ON

Financials (06/30/19)

Cash on hand: $3.1 billion
Fixed Investment: $1.4 billion
Shareholders’ Equity: $5.6 billion
Net Revenue – Last Quarter: $90.5 million
Adj. Gross Margin: 14.6%
EPS: $-3.70

Capital Structure (08/14/19)

Last Financing: $5 billion Constellation Investment
Basic Shares: 347.9 million
Warrants: 159.1 million
Options: 29.1 million
Diluted Shares: 548.4 million

Company Brief

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. The Company has also expanded its brand portfolio with the acquisition of Hiku Brands.

Canopy Growth has 4.4 million square feet of licensed growing space across Canada and more than 1.3 million square feet of expansion underway. The Company has operations in more than 12 countries across five continents.

The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its ownership of Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development.

Featured Video

Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth.

Canadian Operations

  • A leading publicly traded producer in terms of revenue, grams shipped and registered medical patients
  • 4.4 million-square-foot licensed footprint with plans for expansion to 5.7 million square feet
  • More than 5,000 acres for hemp production
  • Multiple production facilities in provinces including Alberta, British Columbia, Saskatchewan, Ontario, Québec, New Brunswick, and Newfoundland
  • Cannabis supply agreements in Alberta, Quebec, Newfoundland & Labrador, Manitoba, British Columbia, New Brunswick, Nova Scotia,  Saskatchewan, Ontario, Prince Edward Island, Northwest Territory, Nunavut, and the Yukon
  • First publicly-traded LP (April 2014) and first to attain listing on the Toronto Stock Exchange (August 2016) and the New York Stock Exchange (May 2018)
  • $5 billion CAD investment from Constellation Brands
  • Brick-and-mortar presence with Tweed brand and Tokyo Smoke stores in five provinces
  • House of brands including core brands: Tweed, Tokyo Smoke, Van der Pop, DOJA,  and TWD; and affiliated brands: Houseplant, DNA Genetics, LBS, Green House Seeds, and Organa Brands
  • Strategic relationship with operating platform Canopy Rivers and wholly-owned biopharmaceutical subsidiary Canopy Health Innovations
  • Investment in hemp research through Green Hemp Industrie and ebbu acquisitions

Global Operations 

  • Operating across five continents and licensed for more than 35 million square feet of production across Europe, Africa, and South America
  • International subsidiaries and partnerships in Germany, Chile, Colombia, Denmark, Jamaica, Lesotho, Australia, Brazil, Czech Republic, Spain, Poland, the UK, and the United States
  • Export agreements in Australia, Brazil, Czech Republic, Denmark, Germany, and Spain
  • Strong international presence through Spectrum including Spektrum in Germany, Spectrum Demark, Spectrum Czech, Spectrum Australia, Spectrum Lesotho, Spectrum Cannabis Colombia, Spectrum Chile, and Spectrum Peru
    Canopy LATAM, based in Brazil, to advance medical cannabis under the Spectrum brand
  • 49% ownership of Jamaican company Tweed JA
  • New York hemp license and plans to establish commercial operations in the U.S.; plans to invest $100 to $150 million in New York state
  • Hemp company AgriNextUSA acquisition to help spur U.S. expansion plans
  • Cannabinoid-based pharmaceuticals manufacturer C3 added to the company’s global medical brand and portfolio Spectrum Therapeutics
  • A growing IP portfolio with 90 patents and more than 230 applications filed

International Expansion

New West Summit

Groundbreaking Strategic Partnership

Institutional Analyst Coverage


Canaccord Genuity

Cowen and Company

BMO Capital Markets

Bryan Garnier & Co

Stifel Equity Research

BoFA Merrill lynch

Benchmark Capital

Eight Capital

GMP Securities

Altacorp Capital

Compass Point

Cormark Securities

Scotia Capital

Echelon Wealth Partners

PI Financial

Alliance Global Partners

Curated Stories & News

Visit Canopy Growth Corp.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Canopy Growth Corp. is a client of NCV Media, LLC. Read our full disclaimer.